16:33 EDT Septerna (SEPN) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEPN:
- Septerna: Novo-Backed GPCR Platform and Best-in-Class Potential for Oral MRGPRX2 Inhibitor SEP-631 Support Buy Rating
- Septerna reports Q4 EPS (24c), consensus (22c)
- Septerna (SEPN): Early Proof-of-Concept for SEP-631 in Mast Cell–Driven Disease Supports Long-Term Growth Potential
- Septerna price target raised to $40 from $35 at H.C. Wainwright
- Septerna Advances SEP-631 After Positive Phase 1 Results